Designing a study to evaluate the benefit of a biomarker for selecting patient treatment

Statistics in Medicine

Volumn 34, Issue 27, 2015, Pages 3503-3515

  Janes, Holly ^a,b   Brown, Marshall D ^a   Pepe, Margaret S ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biomarker; Predictive marker; Randomized controlled trial; Statistical interaction; Study design; Treatment selection

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ARTICLE; BREAST CANCER; CANCER SURGERY; CASE CONTROL STUDY; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HEALTH CARE UTILIZATION; HUMAN; NODE POSITIVE BREAST CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PROBABILITY; PROCESS DESIGN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIMULATION; STATISTICAL DISTRIBUTION; STUDY DESIGN; TREATMENT INDICATION; BREAST TUMOR; FEMALE; METHODOLOGY; PATIENT SELECTION; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

BIOMARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; MODELS, STATISTICAL; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84945487919     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6564     Document Type: Article

References (41)

1. Sargent D, Allegra C. Issues in clinical trial design for tumor marker studies. Seminars in Oncology 2002; 29(3):222-230.
2. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research 2004; 10:6759-6763.
3. Simon R. Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. European Journal of Cancer 2008; 44(18):2707-2713.
4. Gunter L, Zhu J, Murphy S. Proceedings of the 11th Conference on Artificial Intelligence in Medicine, chap. Variable selection for optimal decision making. Springer Verlag: Amsterdam, 2007.
5. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 2005; 1(11):7872-7878.
6. Mandrekar S, Grothey A, Goetz M, Sargent D. Clinical trial designs for prospective validation of biomarkers. American Journal of Pharmacogenomics 2005; 5(5):317-325.
7. Sargent D, Conley B, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology 2005; 23(9):2020-2027.
8. Simon R, Wang S. The use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics Journal 2006; 6(3):166-173.
9. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute 2007; 99:1036-1043.
10. Simon R. Development and validation of biomarker classifiers for treatment selection. Journal of Statistical Planning and Inference 2008; 138(2):308-320.
11. Lijmer J, Bossuyt P. Various randomized designs can be used to evaluate medical tests. Journal of Clinical Epidemiology 2009; 62(4):364-373.
12. Mandrekar S, Sargent D. Clinical trial designs for predictive biomarker validation: one size does not fit all. Journal of Biopharmaceutical Statistics 2009; 19:530-542.
13. Simon R, Paik S, Hayes D. Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute 2009; 101:1446-1452.
14. Taube S, Clark G, Dancey J, McShane L, Sigman C, Gutman S. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. Journal of the National Cancer Institute 2009; 101:1453-1463.
15. Mandrekar S, Sargent D. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. Journal of Clinical Oncology 2009; 24(24):4027-4034.
16. Clark G, McShane L. Biostatistical considerations in development of biomarker-based tests to guide treatment decisions. Statistics in Biopharmaceutical Research 2011; 3:549-560.
17. Mandrekar S, Sargent D. Predictive biomarker validation in practice: lessons from real trials. Clinical Trials 2010; 7:567-573.
18. McShane L. Statistical challenges in the development and evaluation of marker-based clinical tests. BMC Medicine 2012; 10:52.
19. Freidlin B, McShane L, Korn E. Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute 2010; 102:151-160.
20. Tajik P, Zwinderman AH, Mol BW, Bossuyt PM. Trial designs for personalizing cancer care: a systematic review and classification. Clinical Cancer Research 2013; 19:4578-4588.
21. Janes H, Pepe MS, Bossuyt PM, Barlow WE. Measuring the performance of markers for guiding treatment decisions. Annals of Internal Medicine 2011; 154(4):253-259.
22. Huang Y, Gilbert PB, Janes H. Assessing treatment-selection markers using a potential outcomes framework. Biometrics 2012; 68(3):687-696.
23. Song X, Pepe MS. Evaluating markers for selecting a patient's treatment. Biometrics 2004; 60(4):874-883.
24. Brinkley J, Tsiatis AA, Anstrom KJ. A generalized estimator of the attributable benefit of an optimal treatment regime. Biometrics 2010; 66:512-522.
25. Zhang B, Tsiatis AA, Laber EB, Davidian M. A robust method for estimating optimal treatment regimes. Biometrics 2012.
26. Zhao Y, Zeng D, Rush AJ, Kosorock MR. Estimating individualized treatment rules using outcome weighted learning. Journal of the American Statistical Association 2012; 107:1106-1118.
27. Janes H, Brown MD, Pepe MS, Huang Y. An approach to evaluating and comparing biomarkers for patient treatment selection. International Journal of Biostatistics 2014; 10:99-121.
28. Early Breast Cancer Trialists Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365:1687-1717.
29. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Research 2007; 9:R81.
30. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 2004; 351(27):2817-2826.
31. Paik S, Tang G, Shak S, Chungyeul K, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Constantino JP, Geyer CE Jr., Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen-receptor-positive breast cancer. Journal of Clinical Oncology 2006; 24:3726-3734.
32. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncology 2010; 11:55-65.
33. Janes H, Pepe MS, Huang Y. A framework for evaluating markers used to select patient treatment. Medical Decision Making 2013; 34:159-167.
34. Albain KS, Barlow WE, Davdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK, for The Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomized controlled trial. Lancet 2009; 274:2055-2063.
35. Vickers AJ, Kattan MW, Sargent D. Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials 2007; 8:14.
36. Pusztai L, Hess KR. Clinical trial design for microarray predictive marker discovery and assessment. Annals of Oncology 2004; 15:1731-1737.
37. Simon R. The use of genomics in clinical trial design. Clinical Cancer Research 2008; 14:5954-5958.
38. Cardoso F, Van'tVeer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. Journal of Clinical Oncology 2008; 26:729-735.
39. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clinical Breast Cancer 2006; 7:347-350.
40. Barlow WE. Handbook of Statistics in Clinical Oncology. Design of a Clinical Trial for Testing the Ability of a Continuous Marker to Predict Therapy Benefit. Chapman and Hall/CRC: Boca Raton, FL, 2012.
41. Tajik P, Bossuyt PM. Genomic markers to tailor treatments: waiting or initiating? Human Genetics 2011; 130:15-18.